Astec LifeSciences Limited staged a sharp financial rebound in the fourth quarter of FY26, narrowing losses and boosting income, even as it continued to grapple with full-year challenges.

 

The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year. Operating performance also improved, with EBITDA rising to Rs. 11.8 crore from Rs. 6.3 crore a year ago. Losses, while still present, were significantly reduced to Rs. 7.7 crore compared to Rs. 16.1 crore in Q4 FY25.

 

For the full financial year, the recovery trend was evident but incomplete. Total income climbed to Rs. 453.2 crore in FY26 from Rs. 386.9 crore in FY25. The company reached near EBITDA breakeven at Rs. 0.5 crore, a dramatic turnaround from the Rs. 60.6 crore loss reported last year. 

 

Net loss for the year, after exceptional items and tax, stood at Rs. 80.9 crore—substantially lower than the Rs. 134.7 crore loss in FY25.

 

A portion of the annual loss was attributed to regulatory changes. Pursuant to the notification of four Labour Codes by the Government of India, the Group has assessed the incremental financial impact based on draft rules and ICAI guidance. 

 

The impact arising primarily from the revised wage definition—gratuity Rs. 1.7 crore and long-term compensated absences of Rs. 0.4 crore —has been classified as Exceptional Items due to its regulatory-driven and non-recurring nature, with ongoing monitoring of final rules.

 

Despite continued losses, the latest numbers signal a company clawing its way back, with stronger quarterly momentum and a markedly improved operational footing heading into the new fiscal year.

 

Vishal Sharma, Chairperson, Astec LifeSciences Limited, said: "In Q4FY26, Astec delivered strong revenue growth of 34% y-o-y primarily on the back of improved 

volumes in both the categories, i.e. Enterprise and Contract Manufacturing segment. Revenue increased sequentially as well by 29% over Q3FY26, primarily driven by Enterprise Volumes."

 

"Improved volumes in the Enterprise and CDMO segments drove a significant margin expansion, leading to an increase in EBITDA to Rs. 11.8 crore in Q4FY26 from Rs. 6.3 crore in Q4FY25, an 87% y-o-y growth."